Intellia Therapeutics, Inc. $NTLA Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP cut its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 16.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 261,864 shares of the company’s stock after selling 51,821 shares during the period. Wasatch Advisors LP’s holdings in Intellia Therapeutics were worth $3,357,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in NTLA. Farallon Capital Management LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter worth about $10,486,000. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 1.8% during the third quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after buying an additional 192,651 shares in the last quarter. Contrarius Group Holdings Ltd boosted its holdings in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after buying an additional 4,337,428 shares during the period. Wesbanco Bank Inc. acquired a new position in shares of Intellia Therapeutics in the fourth quarter worth about $575,000. Finally, Canal Insurance CO purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $899,000. 88.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NTLA. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. The Goldman Sachs Group lifted their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Wells Fargo & Company increased their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. Finally, Morgan Stanley raised their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.46.

Intellia Therapeutics Stock Up 4.1%

Shares of NTLA opened at $16.68 on Friday. The company’s fifty day moving average is $13.94 and its 200-day moving average is $12.77. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -4.71 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the previous year, the business earned ($1.10) EPS. As a group, research analysts predict that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.